Immune Therapeutics, Inc.

Immune Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease. Immune Therapeutics is actively developing T-cell activation immunotherapies in combination with other drug candidates to achieve immunomodulation in patients with cancer, auto-immune disease and inflammatory diseases

Recent News

  • Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients

    Winter Park, Florida--(Newsfile Corp. - June 9, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN), announced today that equity partner, Cytocom, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study CYTO-201 for the treatment of COVID-19. The submission has been reviewed by the COVID-19 Scientific/Technical Triage Team and has been assigned for review by the Division of Pulmonology, Allergy and Critical Care (DPACC), part of the Office of...

    2020-06-09 8:41 AM ET
  • Immune Therapeutics, Inc. Focusing to Drive Shareholder Value

    Winter Park, Florida--(Newsfile Corp. - May 6, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company") is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced it has initiated a corporate plan to drive shareholder value.Recent economic events require that Immune revisit its business model and explore new opportunities to drive shareholder value. The Board of Directors is evaluating its technology portfolio, looking to focus...

    2020-05-06 10:07 AM ET
  • Immune Therapeutics Inc and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications

    Immune Therapeutics Announces Settlement with Major Creditors as part of licensing agreementImmune Therapeutics Announces Filing of 10K Extension Under SEC Allowance for COVID19 DisruptionForte Aims to Develop and Commercialize Lodonal and IRT=101 for the Treatment of Cancer and Inflammatory Disease in Companion AnimalsOrlando, Florida--(Newsfile Corp. - April 16, 2020) - Immune Therapeutics Inc. (OTC PINK: IMUN), a clinical-stage pharmaceutical company, and Forte Biotechnology Intl Corp, a privately-held biotech company focused on innovations in the veterinary drug space, today announced...

    2020-04-16 11:54 AM ET
  • Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19

    Orlando, Florida--(Newsfile Corp. - March 20, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), Immune Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease today announced the signing of a binding letter of intent to collaborate with Cytocom, Inc. ("Cytocom" or "CYTO") for the development of Lodonal™ and IRT-101 for use against COVID-19, the disease caused by the new...

    2020-03-20 8:30 AM ET
  • Immune Therapeutics, Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

    Orlando, Florida--(Newsfile Corp. - March 9, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases and cancer today announced an update on the pending 1000-to-1 reverse stock split and name change of Immune Therapeutics.Immune Therapeutics originally submitted the reverse and name change request for a corporate action to FINRA and paid the applicable fees on November 27,...

    2020-03-09 9:00 AM ET
  • Immune Therapeutics, Inc. Appoints New Independent Director

    Fort Collins, Colorado--(Newsfile Corp. - February 18, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company") is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases that has announced the appointment of Mr. Michael L. Sander to its Board of Directors, who will succeed Jack Brewer, who served on the Company's Board of Directors since 2018 and Edward Teraskiewicz, who served on the Company's Board of Directors...

    2020-02-18 11:52 AM ET
  • Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

    Orlando, Florida--(Newsfile Corp. - February 11, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse stock split and name change of Immune Therapeutics.Immune Therapeutics originally submitted the reverse and name request for a corporate action to FINRA and paid the applicable fees on November 27,...

    2020-02-11 9:00 AM ET